Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2F2 | P24468 | 3/20 | 0.53 |
| ▸ | STAT3 | P40763 | 6/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | PEAK1 | Q9H792 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189877 | 0.95 | NR2F2 (0.49) | NR2F2STAT3PDGFRBADRB2ADRB1 | |
| SCHEMBL4188823 | 0.89 | MAOB (0.52) | NR2F2STAT3PDGFRBADRB2ADRB1 | |
| SCHEMBL4198431 | 0.86 | KIT (0.52) | PDGFRBADRB2ADRB1ADRB3CSF1R | |
| SCHEMBL4191906 | 0.84 | MAOB (0.48) | NR2F2STAT3PDGFRBADRB2ADRB1 | |
| SCHEMBL4199286 | 0.82 | PAK1 (0.50) | NR2F2STAT3PDGFRBADRB2ADRB1 | |
| SCHEMBL4968571 | 0.81 | PDGFRB (0.72) | PDGFRBCSF1RKITFLT3 | |
| SCHEMBL4202933 | 0.81 | KIT (0.47) | PDGFRBADRB2ADRB1ADRB3CSF1R | |
| SCHEMBL4965895 | 0.79 | FLT3 (0.57) | PDGFRBKITFLT3 | |
| SCHEMBL4965480 | 0.77 | PDGFRB (0.67) | PDGFRBCSF1RKITFLT3 | |
| SCHEMBL29230284 | 0.76 | STAT3 (0.61) | NR2F2STAT3ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-25 | — | — | US | disclosed |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-25 | — | — | US | disclosed |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-25 | — | — | US | disclosed |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-04 | — | — | US | disclosed |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-04 | — | — | US | disclosed |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-04 | — | — | US | disclosed |
| EP-1899355-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1893215-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135630-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135639-A1 | THIΞNOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES AS FLT-3 KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281769-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060281768-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281768-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, CDK2 | NR2F2 1744/4885STAT3 1093/4885PDGFRB 38/4885 |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, CDK2 | NR2F2 1744/4885STAT3 1093/4885PDGFRB 38/4885 |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, CDK2 | NR2F2 1744/4885STAT3 1093/4885PDGFRB 38/4885 |
| US-20060281769-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, TPX2 | NR2F2 1528/4885STAT3 912/4885PDGFRB 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.